Mosaic Therapeutics, an oncology therapeutics company building the category leader in synergistic precision oncology, today announced the appointment of Thomas Fuchs as CEO. Thomas will lead the company to advance its pipeline of proprietary drug combination programmes into the clinic, and through a planned Series B financing round.
Mosaic is applying its advanced experimental and computational platform to identify oncology combinations that have synergistic activity in biomarker-defined patient populations.
The company’s pipeline of combination programmes is anchored by ASTX029, an ERK1/2 inhibitor, and ASTX295, an MDM2 antagonist, both in-licensed from Astex Pharmaceuticals in April 20251. Mosaic’s first clinical combination study is expected to commence in 2026.
Thomas has over 25 years’ experience in leadership positions across early drug development, commercialisation and life cycle management, serving in senior oncology biopharma leadership roles in both oncology-focused biotech and big pharma.
He was most recently CEO at Cimeio Therapeutics, where he led the early company build backed by a $50m series A financing raise and secured a significant strategic collaboration agreement with Kyowa Kirin.
Previously he spent 15 years at Roche-Genentech, serving in senior leadership roles across the Global Haematology franchise.
As Global Franchise Head, he oversaw development strategy, life cycle management and commercialisation of Roche-Genentech’s haematology portfolio, covering five marketed products with over $8Bn sales, and a range of development-stage assets.
Thomas holds an MBA from the Kellogg School of Management at Northwestern University and a Bachelor of Science in Business Administration from the University of Wisconsin-Stout.
Reference
